Article info
Quality of Life
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy
- Address correspondence and reprint requests to Caroline C. Billingsley, MD, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, The Ohio State University, M210 Starling Loving 320 W 10th Ave, Columbus, OH 43210. E-mail: caroline.billingsley{at}osumc.edu.
Citation
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy
Publication history
- Received January 31, 2015
- Accepted April 21, 2015
- First published September 1, 2015.
Online issue publication
June 18, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2015 by IGCS and ESGO